HGF/c-MET轴通过调节多种机制,有助于CLL细胞存活,使其成为CLL治疗的潜在治疗点
Shihao Liang1, Xiaoya Shao2, Xueqiong Meng3,4,5
1Henan International Joint Laboratory of Thrombosis and Hemostasis, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
Frontiers in pharmacology
|June 16, 2025
概括
肝细胞生长因子 (HGF) 通过激活亲生存途径,促进慢性淋巴细胞白血病 (CLL) 细胞存活. 用capmatinib准HGF/c-MET通路抑制了CLL生长并增强了细胞亡,提供了潜在的新治疗策略.
科学领域:
- 血液学 血液学 血液学
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 的治疗需要新的治疗策略.
- 骨髓微环境在CLL的发病过程中起着至关重要的作用.
- 肝细胞生长因子 (HGF) 参与各种细胞过程.
研究的目的:
- 调查HGF/c-MET信号传递在CLL细胞存活和亡中的作用.
- 评估针对CLL中HGF/c-MET通路的治疗潜力.
主要方法:
- 研究了HGF对CLL细胞信号通路 (AKT,ERK,STAT3) 和抗亡蛋白表达 (BCL-2,MCL-1,BCL-xL) 的影响.
- 使用晶状病毒介导的shRNA来敲击c-MET,HGF受体.
- 服用c-MET抑制剂capmatinib,以评估其对CLL细胞的影响.
主要成果:
- 高基因激活支持生存的途径,并调高抗亡蛋白质,增强CLL细胞对亡的抵抗力.
- 通过c-MET倒置或卡普马提尼布治疗,可以抑制CLL细胞的增殖,促进细胞亡,并阻止细胞循环.
- 卡普马提尼布增强了针对CLL的向治疗方法ABT-199的疗效.
结论:
- HGF/c-MET轴对CLL细胞存活和抵抗细胞亡至关重要.
- 准HGF/c-MET通路是CLL治疗的一个有前途的治疗策略.
- 用HGF/c-MET抑制剂和像ABT-199这样的现有治疗方法进行组合治疗可能会改善结果.
相关概念视频
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


